Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Main Article Content

Jonathan I. Silverberg
Michael Cork
Andreas Wollenberg
Norito Katoh
Louise Abildgaard Steffensen
Azra Kurbasic
Christina Kurre Olsen
Alexandra Kuznetsova
Marie Louise Østerdal
Andreas Westh Vilsbøll
Mette Deleuran

Keywords

Atopic Dermatitis, Biologic, Tralokinumab

Abstract

Abstract not available.

References

1. Barbarot S et al. Allergy 2018; 73: 1284–1293.

2. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

3. Guttman-Yassky E et al. Semin Cutan Med Surg 2017; 36: 100–103.

4. Czarnowicki T et al. J Allergy Clin Immunol 2019; 143: 1–11.

5. Szegedi K et al. J Eur Acad Dermatol Venereol 2015; 29: 2136–2144.

6. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.

7. Bieber T. Allergy 2020; 75: 54–62.

8. Pavel AB et al. J Am Acad Dermatol 2020; 82: 690–699.

9. Popovic B et al. J Mol Biol 2017; 429: 208–219.

10. Mercieca-Bebber R et al. Patient Relat Outcome Meas 2018; 9: 353–367.